Search

Your search keyword '"Perotti, C"' showing total 329 results
Start Over Author "Perotti, C" Language english
329 results on '"Perotti, C"'

7. CFU-GM Growth from Peripheral Blood Stem Cells (PBSC) Before and After Cryopreservation : Comparison with Bone Marrow Cells

Author

Bonfichi, M., Brera, C., Balduini, A., Alessandrino, E. P., Bernasconi, P., Troletti, D., Boni, M., Castagnola, C., Brusamolino, E., Pagnucco, G., Perotti, C., Salvaneschi, L., Bernasconi, C., Abraham, Nader G., editor, Asano, Shigetaka, editor, Brittinger, Günther, editor, Maestroni, Georges J. M., editor, and Shadduck, Richard K., editor

Published
1996
Full Text
View/download PDF

10. Impact of in-hospital intravenous iron supplementation on red blood cell transfusions: experience from an Internal Medicine Unit

Author

Bergamaschi G., Livraghi A., Aronico N., Barteselli C., Bonadeo E., Del Rio V., Gabba M., Gentile L., Mengoli C., Perotti C., Di Sabatino A., Bergamaschi, G., Livraghi, A., Aronico, N., Barteselli, C., Bonadeo, E., Del Rio, V., Gabba, M., Gentile, L., Mengoli, C., Perotti, C., and Di Sabatino, A.

Subjects
Anemia, Iron-Deficiency, Iron, Dietary Supplements, Aftercare, Humans, Iron Deficiencies, Erythrocyte Transfusion, Maltose, Ferric Compounds, Hospitals, Patient Discharge, Retrospective Studies
Abstract

BACKGROUND: Pharmacological treatment of iron deficiency anaemia can reduce red blood cell (RBC) transfusions. Intravenous iron provides a more effective and quicker correction of iron deficiency anaemia than oral iron, and third-generation high-dose intravenous iron formulations allow the complete correction of iron deficiency with just one or two drug infusions, thus facilitating iron supplementation therapy and reducing transfusion requirement. MATERIAL AND METHODS: In an observational, retrospective study we compared RBC transfusion requirement during hospitalisation and within 3 months of hospital discharge in 88 patients with iron deficiency anaemia treated with high-dose ferric carboxymaltose and in 85 patients treated with ferric gluconate while hospitalised in the Internal Medicine unit of our Institution. RESULTS: Ferric carboxymaltose reduced the number of RBC units given to each transfused patient during hospitalisation (1.81±0.84 vs 2.39±1.49, p=0.011). At hospital discharge, fewer ferric carboxymaltose patients were prescribed home therapy with iron. No differences between treatment groups were observed in the proportion of patients or the number of RBC units transfused within 3 months of discharge. At one month from discharge, however, only 2 ferric carboxymaltose patients had been transfused compared with 7 ferric gluconate patients (p=0.078). Patients transfused post-discharge were more likely to have an underlying malignancy and/or higher serum creatinine concentrations. DISCUSSION: Treatment with ferric carboxymaltose reduced the number of RBC units per transfused patient. Larger studies are required to define risk factors associated with post-discharge transfusion requirement and to establish if home therapy with iron will reduce subsequent transfusions in patients treated with ferric carboxymaltose.

Published
2021

16. Severe immunoglobulin A vasculitis with refractory gastrointestinal involvement in an adult patient successfully treated with plasma exchange.

Author

Codullo, V, Monti, S, Perotti, C, Milanesi, A, Rossi, S, Gallotti, A, Cobianchi, L, Montecucco, C, and Delvino, P

Subjects
TREATMENT effectiveness, VASCULITIS, SURGERY, REFRACTORY materials, ANATOMICAL planes, ACUTE abdomen
Abstract

Immunoglobulin A vasculitis (IgAV) is a systemic vasculitis that is more common in children and tends to have a better outcome in that population. However, it is rarer in adults and can be associated with worse outcomes. Gastrointestinal involvement is common in adult IgAV patients, but there is limited consensus on how to treat this manifestation. This article describes a case of a 24-year-old man with severe IgAV and refractory gastrointestinal involvement who was successfully treated with plasma exchange (PEX) and cyclophosphamide. This is the first reported case of PEX being effective in an adult with IgAV and life-threatening gastrointestinal symptoms. The patient achieved clinical remission and had no signs of relapse after 18 months. The authors suggest that PEX should be considered in cases of severe IgAV with gastrointestinal involvement. [Extracted from the article]

Published
2024
Full Text
View/download PDF

17. Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients with COVID-19 Pneumonia: A Randomized Clinical Trial

Author

Menichetti, F., Popoli, P., Puopolo, M., Alegiani, S. S., Tiseo, G., Bartoloni, A., De Socio, G., Luchi, S., Blanc, P., Puoti, M., Toschi, E., Massari, M., Palmisano, L., Marano, G., Chiamenti, M., Martinelli, L., Franchi, S., Pallotto, C., Suardi, L. R., Pasqua, B. L., Merli, M., Fabiani, P., Bertolucci, L., Borchi, B., Modica, S., Moneta, S., Marchetti, G., d'Arminio Monforte, A., Stoppini, L., Ferracchiato, N., Piconi, S., Fabbri, C., Beccastrini, E., Saccardi, R., Giacometti, A., Esperti, S., Pierotti, P., Bernini, L., Bianco, C., Benedetti, S., Lanzi, A., Bonfanti, P., Sani, S., Saracino, A., Castagna, A., Trabace, L., Lanza, M., Focosi, D., Mazzoni, A., Pistello, M., Falcone, M., Locatelli, F., Ippolito, G., Magrini, N., Bernardini, R., Brusaferro, S., De Angelis, V., Perotti, C., Remuzzi, G., De Silvestro, G., Costantini, M., Bocchino, M., De Donno, G., Francisci, D., Menichetti, F., Popoli, P., Puopolo, M., Spila Alegiani, S., Tiseo, G., Bartoloni, A., De Socio, G. V., Luchi, S., Blanc, P., Puoti, M., Toschi, E., Massari, M., Palmisano, L., Marano, G., Chiamenti, M., Martinelli, L., Franchi, S., Pallotto, C., Suardi, L. R., Luciani Pasqua, B., Merli, M., Fabiani, P., Bertolucci, L., Borchi, B., Modica, S., Moneta, S., Marchetti, G., D'Arminio Monforte, A., Stoppini, L., Ferracchiato, N., Piconi, S., Fabbri, C., Beccastrini, E., Saccardi, R., Giacometti, A., Esperti, S., Pierotti, P., Bernini, L., Bianco, C., Benedetti, S., Lanzi, A., Bonfanti, P., Sani, S., Saracino, A., Castagna, A., Trabace, L., Lanza, M., Focosi, D., Mazzoni, A., Pistello, M., Falcone, M., Menichetti, F, Popoli, P, Puopolo, M, Spila Alegiani, S, Tiseo, G, Bartoloni, A, De Socio, G, Luchi, S, Blanc, P, Puoti, M, Toschi, E, Massari, M, Palmisano, L, Marano, G, Chiamenti, M, Martinelli, L, Franchi, S, Pallotto, C, Suardi, L, Luciani Pasqua, B, Merli, M, Fabiani, P, Bertolucci, L, Borchi, B, Modica, S, Moneta, S, Marchetti, G, d'Arminio Monforte, A, Stoppini, L, Ferracchiato, N, Piconi, S, Fabbri, C, Beccastrini, E, Saccardi, R, Giacometti, A, Esperti, S, Pierotti, P, Bernini, L, Bianco, C, Benedetti, S, Lanzi, A, Bonfanti, P, Sani, S, Saracino, A, Castagna, A, Trabace, L, Lanza, M, Focosi, D, Mazzoni, A, Pistello, M, and Falcone, M

Subjects
Male, medicine.medical_specialty, Randomization, Settore MED/17 - Malattie Infettive, Population, Aged, COVID-19, Disease Progression, Female, Humans, Italy, Middle Aged, Prospective Studies, SARS-CoV-2, Severity of Illness Index, Standard of Care, Hospital Mortality, Hospitalization, Immunization, Passive, Plasma, Respiratory Insufficiency, Passive, law.invention, Randomized controlled trial, law, Internal medicine, Clinical endpoint, medicine, education, Adverse effect, education.field_of_study, business.industry, General Medicine, Odds ratio, medicine.disease, Pneumonia, Respiratory failure, Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA, Immunization, business
Abstract

Importance: Convalescent plasma (CP) has been generally unsuccessful in preventing worsening of respiratory failure or death in hospitalized patients with COVID-19 pneumonia. Objective: To evaluate the efficacy of CP plus standard therapy (ST) vs ST alone in preventing worsening respiratory failure or death in patients with COVID-19 pneumonia. Design, setting, and participants: This prospective, open-label, randomized clinical trial enrolled (1:1 ratio) hospitalized patients with COVID-19 pneumonia to receive CP plus ST or ST alone between July 15 and December 8, 2020, at 27 clinical sites in Italy. Hospitalized adults with COVID-19 pneumonia and a partial pressure of oxygen-to-fraction of inspired oxygen (Pao2/Fio2) ratio between 350 and 200 mm Hg were eligible. Interventions: Patients in the experimental group received intravenous high-titer CP (≥1:160, by microneutralization test) plus ST. The volume of infused CP was 200 mL given from 1 to a maximum of 3 infusions. Patients in the control group received ST, represented by remdesivir, glucocorticoids, and low-molecular weight heparin, according to the Agenzia Italiana del Farmaco recommendations. Main outcomes and measures: The primary outcome was a composite of worsening respiratory failure (Pao2/Fio2 ratio

Published
2021

46. Phenotypical/functional characterization of in vitro-expanded mesenchymal stromal cells from patients with Crohn's disease BM-derived MSC from patients with Crohn's disease

Author

Bernardo M. E., Avanzini M. A., Ciccocioppo R., Perotti C., Cometa A. M., Moretta A., Marconi M., Valli M., Novara F., Bonetti F., Zuffardi O., MacCario R., Corazza G. R., Locatelli F., Bernardo, M. E., Avanzini, M. A., Ciccocioppo, R., Perotti, C., Cometa, A. M., Moretta, A., Marconi, M., Valli, M., Novara, F., Bonetti, F., Zuffardi, O., Maccario, R., Corazza, G. R., and Locatelli, F.

Subjects
In vitro expansion, Adult, Male, Adolescent, Multipotent Stem Cells, Stem Cells, Mesenchymal stromal cells, Cell Differentiation, Mesenchymal Stem Cells, Middle Aged, Mesenchymal Stem Cell Transplantation, Reparative medicine, Immunophenotyping, Crohn's disease, Crohn Disease, Bone Marrow, Humans, Female, Infl ammation, Cell Proliferation
Abstract

Background aims Because of their capacity to modulate the immune response and promote tissue repair, mesenchymal stromal cells (MSC) represent a potential novel treatment for autoimmune/inflammatory diseases, including Crohn's disease (CD). The aim of the study was in vitro characterization of MSC from active CD patients for future clinical application. Methods MSC from the bone marrow (BM) of seven CD patients (median age 32 years) were expanded ex vivo in the presence of 5% platelet lysate; cells were investigated for clonogenic efficiency, proliferative capacity, morphology, immunophenotype, differentiation potential, genetic stability and ability to suppress in vitro proliferation of both autologous and allogeneic lymphocytes to polyclonal mitogens. Results were compared with those of BM MSC of four healthy donors (HD). Results MSC were successfully expanded from all patients. Colony-forming unitfibroblast (CFU-F) frequency and proliferative capacity were comparable in CD and HD MSC. CD MSC showed typical spindle-shaped morphology and differentiated into osteoblasts, adipocytes and chondrocytes. Surface immunologic markers did not differ between CD and HD MSC, with the only exception of sizeable levels of HLA-DR at early culture passages [1284% at passage (P)1] in the former. CD MSC ceased their growth at variable passages (from P8 to P25) and entered senescence without any change in morphology/proliferation rate. Array-comparative genomic hybridization demonstrated that CD MSC do not show imbalanced chromosomal rearrangements. Both CD and HD MSC inhibited in vitro proliferation of lymphocytes to mitogens. Conclusions CD MSC show biologic characteristics similar to HD MSC and can be considered for anti-inflammatory and reparative cell therapy approaches in patients with refractory disease. © 2009 ISCT.

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results